GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » 5-Year Yield-on-Cost %

Imunon (Imunon) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Imunon 5-Year Yield-on-Cost %?

Imunon's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Imunon's 5-Year Yield-on-Cost % or its related term are showing as below:



IMNN's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.92
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Imunon's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Imunon's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Imunon's 5-Year Yield-on-Cost % falls into.



Imunon 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Imunon is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Imunon  (NAS:IMNN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Imunon 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Imunon's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon (Imunon) Business Description

Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Executives
James E Dentzer director C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne director, officer: President and CEO 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno officer: Chief Executive Offier 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John officer: Chief Accounting Officer C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg director C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church officer: Chief Financial Officer
Robert W Hooper director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc. 10 percent owner 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer officer: Chief Scientific Officer C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107

Imunon (Imunon) Headlines

From GuruFocus

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

By sperokesalga sperokesalga 03-21-2023